Articles

  • 3 weeks ago | aei.org | James Pethokoukis |Sally Satel |Kirsten Axelsen |Peter Pitts

    Post Washington Should Fund More Potential Science Miracles Article Up Wing/Down Wing #43 Article Up Wing/Down Wing #42 Article Up Wing/Down Wing #41 Article Up Wing/Down Wing #40 Article Up Wing/Down Wing #39 Article Up Wing/Down Wing #38 Article A Twist on the Notion That Big Ideas Are Getting Harder To Find Article Medical Schools’ Botched Pass-Fail Experiment Post Seizing Intellectual Property for Medicines Is Not a Path to Prosperity Article The Future of Weight Loss Drugs: A Quick Q&A...

  • 1 month ago | aei.org | Henry Olsen |With Colin Dueck |Colin Dueck |Kirsten Axelsen

    While known to be traditionally predictable, Canada’s recent snap federal election has been anything but. Early this January, polling showed that the Liberal Party of Canada was on track to suffer one of the largest political defeats in Canadian history, induced by public dissatisfaction with former Prime Minister Justin Trudeau’s administration. However, the months preceding this election showed a surge in Liberal support driven by national pride and economic uncertainty.

  • Nov 13, 2024 | aei.org | Kirsten Axelsen

    The U.S. is the most important market for drug development. The country has rapid scientific reviews and drug approvals, and typically a quick and predictable pathway to reimbursement. It is unfortunate, then, that our policymakers are borrowing ideas from countries that have destroyed incentives to invest in their life sciences economies and reduced their citizens’ access to life-changing treatments. If we borrow these bad ideas, we will also borrow their bad outcomes.

  • Oct 28, 2024 | itif.org | Sandra Barbosu |Kirsten Axelsen |Stephen Ezell

    KEY TAKEAWAYSThere is a pressing need for updated, robust evidence to inform biopharmaceutical policy. This need is especially urgent in light of recent initiatives such as the Inflation Reduction Act (IRA), which instituted price-setting provisions that would lead to reduced R&D investment and a large decrease in new drugs developed.

  • Oct 23, 2024 | itif.org | Kirsten Axelsen |Sandra Barbosu |Stephen Ezell

    The Information Technology and Innovation Foundation (ITIF) convened an expert symposium on October 10, 2024, to discuss the evidence that is currently available to assess financial returns from clinical development of biopharmaceuticals, and to consider related questions such as how investors measure financial returns, how drug development has evolved in the past 10 years, what kind of information is most useful in guiding biopharmaceutical policy, and what factors drive further innovation...

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →